Wells Fargo’s Vor Biopharma VOR Stock Holding History

Wells Fargo’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18	Hold	1	–	–	﹤0.01%	6830
2025 Q4	$13	Hold	1	–	–	﹤0.01%	6834
2025 Q3	$49	Buy	+1	New	+$40	﹤0.01%	6495
2024 Q2	–	Sell	-674	Closed	-$32K	–	7503
2024 Q1	$32K	Buy	674 +93	+16%	+$4.08K	﹤0.01%	5425
2023 Q4	$26.1K	Buy	581 +115	+25%	+$4.75K	﹤0.01%	5541
2023 Q3	$19.8K	Sell	466 -250	-35%	-$13.6K	﹤0.01%	5604
2023 Q2	$44.2K	Buy	716 +705	+6,409%	+$64.4K	﹤0.01%	5469
2023 Q1	$1.19K	Buy	11 +5	+83%	+$554	﹤0.01%	6331
2022 Q4	$771	Hold	6	–	–	﹤0.01%	6270
2022 Q3	$0	Buy	6 +2	+50%	+$197	﹤0.01%	7447
2022 Q2	$0	Sell	4 -17	-81%	-$1.74K	﹤0.01%	7575
2022 Q1	$3K	Sell	21 -337	-94%	-$57.4K	﹤0.01%	6606
2021 Q4	$83K	Buy	358 +356	+17,800%	+$103K	﹤0.01%	5736
2021 Q3	$0	Sell	2 -2	-50%	-$595	﹤0.01%	7582
2021 Q2	$2K	Sell	4 -174	-98%	-$85.9K	﹤0.01%	6568
2021 Q1	$153K	Buy	+178	New	+$151K	﹤0.01%	5287

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wells Fargo's VOR Position: Q1 2026 in Review

Wells Fargo held its Vor Biopharma (VOR) position steady in Q1 2026 at 1 share worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #6830.

Wells Fargo first reported a position in VOR in Q1 2021 and has held it in 16 quarters since. The position peaked at $153K in Q1 2021. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

Wells Fargo held 1 share of Vor Biopharma worth $18 as of Q1 2026.
Wells Fargo left its Vor Biopharma share count unchanged in Q1 2026.
Vor Biopharma made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6830 holding.
Wells Fargo first reported a position in Vor Biopharma in Q1 2021 and has held it in 16 quarters since.
Wells Fargo's Vor Biopharma position peaked at $153K in Q1 2021.
80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.